Page 39 - 2019_04-Haematologica-web

Allogeneic SCT for myelofibrosis
potential reductions in the risks of GvHD and relapse, although these need confirmation. Alertness to potential infectious complications is warranted. How the role of other novel agents will fit into the transplant paradigm
remains unknown. Current challenges regarding allogene- ic SCT are to reduce the relapse risk and rates of NRM, particularly when using alternative donors, and optimiza- tion of graft function.
References
1. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to con- stitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148
2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myelo- proliferative disorders. N Engl J Med. 2005;352(17):1779-1790.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential throm- bocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4),387–97
4. Baxter EJ, Scott LM, Campbell PJ, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myelo- proliferative disorders. Lancet. 2005;365 (9464):1054-1061.
5. HarrisonC,KiladjianJJ,Al-AliHK,etal.JAK inhibition with ruxolitinib versus best avail- able therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798
6. VerstovsekS,MesaRA,GotlibJ,etal.Adou- ble-blind, placebo-controlled trial of ruxoli- tinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.
7. Bose P, Verstovsek S. Developmental thera- peutics in myeloproliferative neoplasms.
Clin Lymphoma Myeloma Leuk. 2017;17S:S43-S52.
8. CervantesF,DupriezB,PereiraA,etal.New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13),2895-2901.
9. PassamontiF,CervantesF,VannucchiAM,et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
10. Gangat N, Caramazza D, Vaidya R, et al. DIPSS-Plus: a refined Dynamic International Prognostic Scoring System (DIPSS) for pri- mary myelofibrosis that incorporates prog- nostic information from karyotype, platelet count and transfusion status. J Clin Oncol. 2011;29(4):392-397.
11. Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010;115(3):496-499.
12. Kröger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofi- brosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29(11):2126–2133.
13. KrögerN,GiorginoT,ScottBL,etal.Impact of allogeneic stem cell transplantation on sur- vival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125(21):3347-3350
14. Grinfeld J, Nangalia, J, Baxter EJ, et al. Personalized prognostic predictions for Patients with myeloproliferative neoplasms
through integration of comprehensive genomic and clinical information. Blood. 2017;130(Suppl 1):491.
15. Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to pre- dict survival in patients with post poly- cythemia vera and post essential thrombo- cythemia myelofibrosis. Leukemia. 2017;31 (12):2726-2731.
16. Scott BL, Gooley T, Linenberger M, et al. International Working Group scores predict post-transplant outcomes in patients with myelofibrosis. Blood. 2010;116(21):3085.
17. Scott BL, Gooley TA, Sorror M, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood. 2012;119(11):2657-2664
18. Gagelmann N, Eikema DJ, Koster L, et al. Comparative performance of prognostic sys- tems in patients with myelofibrosis second- ary to PV and ET after allogeneic stem-cell transplantation. EHA Meeting 2018;Abstract S129.
19. Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062-1069.
20. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecu- lar prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494-1500.
21. Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014;28(7): 1568-1570
22. Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofi- brosis: an international study of 797 patients. Leukemia. 2014;28(9):1804-1810.
23. Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-enhanced International Prognostic Score System for transplantation- age patients wth primary myelofibrosis. J Clin Oncol. 2018;36(4):310-318.
24. Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ version 2.0: mutation and kary- otype-enhanced International Prognostic Scoring System for primary myelofibrosis. J Clin Oncol. 2018;36(17): 1769-1770.
25. Guardiola P, Anderson J.E, Bandini G, et al. Allogeneic stem cell transplantation for agno- genic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood. 1999;93(9):2831–2838.
26. Nivison-Smith I, Dodds AJ, Butler J, et al. Allogeneic hematopoietic cell transplanta- tion for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk. Biol Blood Marrow Transplant. 2012;18(2):302 –308.
27. Abelsson J, Merup M, Birgegard G, et al. The outcome of allo-HSCT for 92 patients with
myelofibrosis in the Nordic countries. Bone
Marrow Transplant. 2011;47(3):380–386.
28. Samuelson S, Sandmaier B.M, Heslop HE, et al. Allogeneic haematopoietic cell transplan- tation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol. 2011;153(1):76–
82.
29. Muffly LS, Kocherginsky M, Stock W, et al.
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplan- tation recipients. Haematologica. 2014;99(8): 1373-1379
30. Robin M, Tabrizi R, Mohty M, et al. Allogeneic haematopoietic stem cell trans- plantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol. 2011;152(3):331-339.
31. Mesa R.A, Nagorney D.S, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: out- comes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107(2):361–370.
32. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicen- ter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114 (26):5264–5270
33. Robin M, Zine M, Chevret S, et al. The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017;23(6):958-964.
34. McLornan D, Szydlo R, Robin M, et al. Outcome of myeloablative and reduced- intensity conditioned allogeneic haematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the EBMT. Annual EBMT meeting. 2018; OS 5-5
35. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibro- sis. Biol Blood Marrow Transplant. 2010;16(3):358–367.
36. Matsubara E, Yamanouchi J, Kitazawa R, et al. Usefulness of low-dose splenic irradiation prior to reduced-intensity conditioning regi- men for hematopoietic stem cell transplanta- tion in elderly patients with myelofibrosis. Case Rep Hematol. 2016;2016:8751329.
37. Kalman NS, Mukhopadhyay ND, Roberts CH, et al. Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis. Leuk Lymphoma. 2017;58(12):2983-2984.
38. Jaekel N, Behre G, Behning A, et al. Allogeneic hematopoietic cell transplanta- tion for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014;49(2): 179- 184.
39. Stübig T, Alchalby H, Ditschkowski M, et al. JAK inhibition with ruxolitinib as pretreat- ment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 2014;28(8):1736-1738
haematologica | 2019; 104(4)
667